What is NewGenIvf Group Limited Warrants's earnings per share (EPS)?

NewGenIvf Group Limited Warrants (NIVFW) reported diluted earnings per share of $27.36 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NewGenIvf Group Limited Warrants (NIVFW) Financials

NIVFW

FY2025 annual

Revenue $4.7M -13.0% YoY

Net Income $9.9M +1983.1% YoY

EPS (Diluted) $27.36 YoY not available

Free Cash Flow -$11.1M -33.0% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Sep 10, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Sep 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIVFW SEC filings page.

NewGenIvf Group Limited Warrants (NIVFW) reported $4.7M in revenue for fiscal year 2025, down 13.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NIVFW FY2025 2026-10-04

FY2025 shows a business whose reported profit was separated from operations, as costs expanded while cash outflows deepened.

Earnings quality weakened sharply: FY2025 reported net income of $9.9M alongside operating cash flow of -$10.9M and free cash flow of -$11.1M. That gap means the accounting profit did not translate into cash from the business's operating activity.

Revenue fell to $4.7M in FY2025 while gross margin narrowed to 20.2% from 33.6% in FY2024; meanwhile, selling and administrative expense reached $10.5M, indicating that overhead—not merely weaker sales—drove the operating loss.

The balance sheet expanded sharply: assets reached $32.7M while liabilities were $6.7M, and reported financing inflows were $19.0M. With a current ratio of 3.1x, short-term coverage improved, but the expansion appears tied more to financing activity than internally generated cash.

Financial Health Signals

Financial health score not available

NewGenIvf Group Limited Warrants does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/8

NewGenIvf Group Limited Warrants passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$1.11used

For every $1 of reported earnings, NewGenIvf Group Limited Warrants used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

NewGenIvf Group Limited Warrants reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$759K

YoY+65.7%

QoQ+65.7%

NewGenIvf Group Limited Warrants held $759K in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

26,736

NewGenIvf Group Limited Warrants had 26,736 shares outstanding in Q4 2025.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

NIVFW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NIVFW quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Revenue	$4.7M-13.0%	$5.4M+5.8%	$5.1M-13.6%	$5.9M+44.3%	$4.1M
Cost of Revenue	$3.8M+4.6%	$3.6M+4.4%	$3.5M-21.6%	$4.4M+42.4%	$3.1M
Gross Profit	$956K-47.7%	$1.8M+8.6%	$1.7M+9.4%	$1.5M+50.1%	$1.0M
SG&A Expenses	$10.5M+277.3%	$2.8M+71.5%	$1.6M+47.0%	$1.1M+37.6%	$801K
Operating Income	-$10.7M-824.3%	-$1.2M-2847.3%	$42K-89.4%	$399K+100.6%	$199K
EBITDA	-$10.5M-823.6%	-$1.1M-1654.2%	$73K-85.3%	$499K+36.6%	$365K
Interest Expense	$616K-19.4%	$765K+1557.0%	$46K	N/A	N/A
Income Tax	N/A	-$487K	N/A	$208K-29.4%	$295K
Net Income	$9.9M+1983.1%	-$525K-503.0%	$130K-71.6%	$459K+86153.8%	-$533
EPS (Basic)	$1932.59+104.9%	-$39678.88-133.9%	$117173.70+2482393.6%	$4.72	$0.00
EPS (Diluted)	$27.36	-$39678.88	$117173.70	$4.72	$0.00
Diluted Shares (Avg)	361,113	13	1	28,797-94.9%	560,000

Metric	Q4'2510-K	Q4'2410-K	Q4'2310-K	Q4'2210-K

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

NIVFW Balance Sheet

NIVFW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Total Assets	$32.7M+814.6%	$3.6M-20.3%	$4.5M+54.5%	$2.9M	N/A
Current Assets	$7.4M+132.7%	$3.2M+29.0%	$2.5M+2.5%	$2.4M	N/A
Cash & Equivalents	$759K+65.7%	$458K+746.0%	$54K+96.3%	$28K-4.2%	$29K
Short-Term Investments	$0	$0	$0	$0	$0
Inventory	$335K+315.0%	$81K-36.0%	$126K+169.2%	$47K	N/A
Accounts Receivable	$167K+238.2%	$49K+425.3%	$9K-27.9%	$13K	N/A
Long-Term Investments	$0	$0	$0	$0	$0
Total Liabilities	$6.7M+33.1%	$5.1M+307.6%	$1.2M-55.7%	$2.8M	N/A
Current Liabilities	$2.4M-13.0%	$2.7M+142.4%	$1.1M-56.1%	$2.6M	N/A
Non-Current Liabilities	$4.4M+86.8%	$2.3M+1866.0%	$119K-52.1%	$249K	N/A
Total Equity	$26.6M+2639.7%	-$1.0M-128.1%	$3.7M+563.4%	$563K+161.5%	-$915K
Retained Earnings	$8.9M+1002.0%	-$986K-113.7%	-$461K+22.0%	-$592K	N/A

Metric	Q4'2510-K	Q4'2410-K	Q4'2310-K	Q4'2210-K
Total Assets	$32.7M+814.6%	$3.6M-20.3%	$4.5M+54.5%	$2.9M
Current Assets	$7.4M+132.7%	$3.2M+29.0%	$2.5M+2.5%	$2.4M
Cash & Equivalents	$759K+65.7%	$458K+746.0%	$54K+96.3%	$28K
Short-Term Investments	$0	$0	$0	$0
Inventory	$335K+315.0%	$81K-36.0%	$126K+169.2%	$47K
Accounts Receivable	$167K+238.2%	$49K+425.3%	$9K-27.9%	$13K
Long-Term Investments	$0	$0	$0	$0
Total Liabilities	$6.7M+33.1%	$5.1M+307.6%	$1.2M-55.7%	$2.8M
Current Liabilities	$2.4M-13.0%	$2.7M+142.4%	$1.1M-56.1%	$2.6M
Non-Current Liabilities	$4.4M+86.8%	$2.3M+1866.0%	$119K-52.1%	$249K
Total Equity	$26.6M+2639.7%	-$1.0M-128.1%	$3.7M+563.4%	$563K
Retained Earnings	$8.9M+1002.0%	-$986K-113.7%	-$461K+22.0%	-$592K

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

NIVFW Cash Flow Statement

NIVFW quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Operating Cash Flow	-$10.9M-32.2%	-$8.3M-367.9%	-$1.8M-203.2%	$1.7M+19.4%	$1.4M
Depreciation & Amortization	$188K+864.6%	$20K-37.4%	$31K-69.0%	$101K-39.7%	$167K
Stock-Based Compensation	N/A	N/A	N/A	$240K+20.0%	$200K
Capital Expenditures	$135K+154.5%	$53K-24.1%	$70K-26.0%	$94K+469.8%	$17K
Free Cash Flow	-$11.1M-33.0%	-$8.3M-353.0%	-$1.8M-213.6%	$1.6M+14.1%	$1.4M
Investing Cash Flow	-$7.6M-14151.6%	-$53K+24.1%	-$70K+26.0%	-$94K-469.8%	-$17K
Financing Cash Flow	$19.0M+118.9%	$8.7M+361.1%	$1.9M+215.2%	-$1.6M-5.8%	-$1.5M

Metric	Q4'2510-K	Q4'2410-K	Q4'2310-K	Q4'2210-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

NIVFW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NIVFW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Gross Margin	20.2%-13.4pp	33.6%+0.9pp	32.7%+6.9pp	25.9%+1.0pp	24.9%
Operating Margin	-226.9%	-21.4%-22.2pp	0.8%-5.9pp	6.7%+1.9pp	4.8%
Net Margin	209.0%	-9.7%-12.2pp	2.5%-5.2pp	7.7%+7.7pp	0.0%
Return on Equity	37.1%	N/A	3.5%-78.0pp	81.5%	N/A
Return on Assets	30.2%+44.9pp	-14.7%-17.6pp	2.9%-12.9pp	15.8%	N/A
Current Ratio	3.12+2.0x	1.17-1.0x	2.19+1.3x	0.94	N/A
Debt-to-Equity	0.25	N/A	0.33-4.6x	4.98	N/A
Asset Turnover	0.14-1.4x	1.52+0.4x	1.14-0.9x	2.05	N/A
FCF Margin	-234.0%	-153.1%	-35.8%-62.9pp	27.2%-7.2pp	34.4%

Metric	Q4'2510-K	Q4'2410-K	Q4'2310-K	Q4'2210-K
Current Ratio	3.12+2.0x	1.17-1.0x	2.19+1.3x	0.94
Debt-to-Equity	0.25	N/A	0.33-4.6x	4.98

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Where NewGenIvf Group Limited Warrants Ranks

Frequently Asked Questions

What is NewGenIvf Group Limited Warrants's annual revenue?

NewGenIvf Group Limited Warrants (NIVFW) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NewGenIvf Group Limited Warrants's revenue growing?

NewGenIvf Group Limited Warrants (NIVFW) revenue declined by 13.0% year-over-year, from $5.4M to $4.7M in fiscal year 2025.

Is NewGenIvf Group Limited Warrants profitable?

Yes, NewGenIvf Group Limited Warrants (NIVFW) reported a net income of $9.9M in fiscal year 2025.

What is NewGenIvf Group Limited Warrants's EBITDA?

NewGenIvf Group Limited Warrants (NIVFW) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is NewGenIvf Group Limited Warrants's gross margin?

NewGenIvf Group Limited Warrants (NIVFW) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is NewGenIvf Group Limited Warrants's return on equity (ROE)?

NewGenIvf Group Limited Warrants (NIVFW) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NewGenIvf Group Limited Warrants's free cash flow?

NewGenIvf Group Limited Warrants (NIVFW) recorded an outflow of $11.1M in free cash flow during fiscal year 2025. This represents a -33.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NewGenIvf Group Limited Warrants's operating cash flow?

NewGenIvf Group Limited Warrants (NIVFW) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are NewGenIvf Group Limited Warrants's total assets?

NewGenIvf Group Limited Warrants (NIVFW) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are NewGenIvf Group Limited Warrants's capital expenditures?

NewGenIvf Group Limited Warrants (NIVFW) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does NewGenIvf Group Limited Warrants have outstanding?

NewGenIvf Group Limited Warrants (NIVFW) had 26,736 shares outstanding as of fiscal year 2025.

What is NewGenIvf Group Limited Warrants's current ratio?

NewGenIvf Group Limited Warrants (NIVFW) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.

What is NewGenIvf Group Limited Warrants's debt-to-equity ratio?

NewGenIvf Group Limited Warrants (NIVFW) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NewGenIvf Group Limited Warrants's return on assets (ROA)?

NewGenIvf Group Limited Warrants (NIVFW) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NewGenIvf Group Limited Warrants's Piotroski F-Score?

NewGenIvf Group Limited Warrants (NIVFW) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NewGenIvf Group Limited Warrants's earnings high quality?

For every $1 of reported earnings, NewGenIvf Group Limited Warrants (NIVFW) used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NewGenIvf Group Limited Warrants cover its interest payments?

NewGenIvf Group Limited Warrants (NIVFW) reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.